Esperion Therapeutics, Inc. (ESPR) - Dilution Analysis

10-Q filing | 251.4M shares outstanding

10-K filing | 256.8M shares outstanding

10-Q filing | 239.1M shares outstanding

8-K filing: Esperion Therapeutics, Inc. entered into an Underwriting Agreement for a public offering of 30,000,000 shares of common stock at $2.50 per share, with an option for the Underwriters to purchase an additional 4,500,000 shares. ($75.0M proceeds)

10-Q filing | 197.5M shares outstanding

10-Q filing | 196.1M shares outstanding

S-3 filing: The filing is an S-3 form registering common stock, preferred stock, debt securities, warrants, and/or units for a total aggregate amount of $400,000,000, in one or more offerings. It also includes an "at the market offering" of common stock for up to $70 million through Cantor.

10-K filing | 187.2M shares outstanding

8-K filing: Esperion Therapeutics, Inc. issued $100 million aggregate principal amount of 5.75% Convertible Senior Subordinated Notes due 2030, exchanging $57.5 million aggregate principal amount of New Notes along with approximately $153.4 million in cash, in exchange for approximately $210.1 million aggregate principal amount of its 4.00% Convertible Senior Subordinated Notes due 2025, and issuing and selling approximately $42.5 million aggregate principal amount of New Notes for cash. ($42.5M proceeds)

8-K filing: Esperion Therapeutics, Inc. entered into privately negotiated exchange and subscription agreements to issue $100 million aggregate principal amount of its 5.75% Convertible Senior Subordinated Notes due 2030 in exchange for 2025 Notes and cash. ($42.5M proceeds)

10-Q filing | 194.9M shares outstanding

10-Q filing | 188.8M shares outstanding

10-Q filing | 189.6M shares outstanding

10-K filing | 185.1M shares outstanding

10-Q filing | 111.9M shares outstanding

10-Q filing | 109.2M shares outstanding

10-Q filing | 94.7M shares outstanding

8-K filing: Esperion Therapeutics, Inc. closed a registered direct offering on March 22, 2023, issuing 12,205,000 shares of common stock, pre-funded warrants for 20,965,747 shares, and warrants for 33,170,747 shares, resulting in gross proceeds of approximately $55.5 million. ($55.54M proceeds)

10-K filing | 76.6M shares outstanding

10-Q filing | 67.8M shares outstanding

10-Q filing | 63.2M shares outstanding

10-Q filing | 61.0M shares outstanding

S-3 filing: The company is filing an S-3 to offer common stock, preferred stock, and debt securities, with the intention to use the net proceeds for commercialization efforts, research and clinical development, working capital, capital expenditures, and general corporate purposes.

10-K filing | 62.8M shares outstanding

8-K filing: Esperion Therapeutics, Inc. completed a firm commitment offering of 32,142,858 shares of common stock and accompanying warrants, with H.C. Wainwright & Co., LLC as the sole book-running manager, raising approximately $208.8 million in net proceeds, with an additional $31.4 million if H.C. Wainwright exercises its option to purchase additional shares of common stock in full. ($225.0M proceeds)

10-Q filing | 26.5M shares outstanding

S-3 filing: Esperion Therapeutics files an S-3 form to offer common stock via an at-the-market offering through Jefferies, with a proposed offering amount of up to $250 million, alongside shelf offerings for common and preferred stock.

10-Q filing | 26.2M shares outstanding

10-Q filing | 28.2M shares outstanding

10-K filing | 27.5M shares outstanding

8-K filing: Esperion Therapeutics, Inc. issued $250 million aggregate principal amount of 4.00% Convertible Senior Subordinated Notes due 2025 and entered into a forward stock purchase transaction to repurchase 1,994,198 shares of its common stock. ($55.0M proceeds)

10-Q filing | 27.9M shares outstanding

10-Q filing | 27.7M shares outstanding

10-Q filing | 27.5M shares outstanding

10-K filing | 26.8M shares outstanding